Portland, OR -- (SBWIRE) -- 09/20/2017 -- Percutaneous transluminal coronary angioplasty (PTCA) is a minimally-invasive procedure used to open blocked or narrowed coronary arteries. PTCA balloons are inflated inside a blocked coronary artery to open up the blockage and allow smooth blood flow. The use of PTCA balloon catheters is on a continuous rise, as it ensures sufficient plaque removal, and optimum patient comfort through a minimally invasive procedure.

Get Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/2635

Increase in aging population and changes in lifestyle of people, technological advancements, changes in FDA policy, and rise in prevalence of cardiovascular disorders are expected to drive the market growth. However, availability of alternative therapies, and complications associated with PTCA balloon catheters restrain this growth. The upsurge in demand for minimally invasive surgeries, rise in disposable incomes, and growth prospects in emerging economies of Asia-Pacific and LAMEA are expected to provide numerous opportunities for market growth during the forecast period.

View Detail Summary of this report: https://www.alliedmarketresearch.com/percutaneous-transluminal-coronary-angioplasty-PTCA-balloon-catheters-market

The normal balloon catheter segment is expected to maintain its dominant position during the analysis period, owing to reduced complications associated with them when compared to other product types. The drug eluting balloon catheter segment is expected to grow at a rapid CAGR of 4.7% throughout the forecast period.

There has been an increased use of drug-eluting balloons in the past few years. The use of drug-eluting balloons has resulted in the reduction in the use of vessel implants (such as stents), which may cause vessel fracture. In addition, drug-eluting balloons are safe and they provide the highest rate of restoration of normal blood flow when compared to other balloon catheters.